marked.bio

RAS peptide vaccine · vaccine

TG01

2 active trials across 2 of our biomarkers, targeting mutant RAS. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 2 2 Phase 1/2
KRAS G12D 2 2 Phase 1/2

Trials

2 of 2 trials shown

  1. The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

    Recruiting Phase 1/2 Oslo University Hospital Started 2023Primary completion 2027-05 NCT05841550

    TG01

    RAS mutation (KRAS/NRAS codon 12/13 mutation) detected on archival or fresh bone marrow material with …

    KRAS G12CKRAS G12DMultiple Myeloma, Smoldering Multiple Myeloma

  2. Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

    Active, not recruiting Phase 2 University of Kansas Medical Center Started 2022Primary completion 2024-12 NCT05638698

    TG01QS-21balstilimab

    Screening tumor tissue positive or known pathogenic or likely pathogenic RAS mutation resulting in amino acid substitution in codon 12A, 12C, 12D, 12R, 12S or 13D .

    KRAS G12CKRAS G12DStatus may be outdated, last updated 2024-09-23Pancreas Cancer